Health Care • Biotechnology: Pharmaceutical Preparations
$11.78 ▼ -0.79
(-6.28%)
MKT CAP: $1.07B • VOL: 1.13M
52W L $9 52W H $23
ROARABLE / RQD
D- • 36/100
PIOTROSKI
2 / 9
MLTX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$244.8M | -$143.1M | -$54.1M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$227.3M | -$118.9M | -$36.0M |
| EBITDA (Normalized) | -$244.8M | -$142.7M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$196.0M | -$116.6M | -$42.8M |
| Capital Expenditures (CapEx) | $35.0K | $520.0K | — |
| Free Cash Flow (FCF) | -$196.0M | -$117.1M | -$42.8M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -42.4% | — |
| Cash & Short-Term Equivalents | $334.5M | $180.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $304.5M | $446.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MLTX.